{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DW+%26+DCE-MRI", "query": { "intervention": "DW & DCE-MRI" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 20, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DW+%26+DCE-MRI&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T04:44:39.607Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05704062", "title": "Quantitative MRI Assessment of Breast Cancer Therapy Response", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Diffusion Weighted Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Corewell Health East", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2010-03-18", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-09-09T04:44:39.607Z", "location_count": 4, "location_summary": "Iowa City, Iowa • Royal Oak, Michigan • Portland, Oregon + 1 more", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Royal Oak", "state": "Michigan" }, { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05704062" }, { "nct_id": "NCT04134468", "title": "MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Pegvorhyaluronidase alfa", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-01", "completion_date": "2022-11-11", "has_results": false, "last_update_posted_date": "2020-01-31", "last_synced_at": "2026-09-09T04:44:39.607Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04134468" }, { "nct_id": "NCT01882231", "title": "Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Osteosarcoma", "Paget's Disease", "Ewing Sarcoma" ], "interventions": [ { "name": "DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 6, "start_date": "2013-03", "completion_date": "2016-04-25", "has_results": false, "last_update_posted_date": "2017-05-08", "last_synced_at": "2026-09-09T04:44:39.607Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01882231" }, { "nct_id": "NCT02241187", "title": "Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "PEGPH20", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "DW & DCE-MRI", "type": "DEVICE" }, { "name": "blood draws", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DEVICE", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2014-09-12", "completion_date": "2016-09-13", "has_results": true, "last_update_posted_date": "2017-09-27", "last_synced_at": "2026-09-09T04:44:39.607Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02241187" }, { "nct_id": "NCT03264300", "title": "Development and Validation of Advanced MRI Methods for Clinical Applications", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain Tumor" ], "interventions": [ { "name": "MRI", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "St. Joseph's Hospital and Medical Center, Phoenix", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2017-06-26", "completion_date": "2022-10-30", "has_results": false, "last_update_posted_date": "2021-09-21", "last_synced_at": "2026-09-09T04:44:39.607Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03264300" }, { "nct_id": "NCT02359565", "title": "Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Constitutional Mismatch Repair Deficiency Syndrome", "Lynch Syndrome", "Malignant Glioma", "Recurrent Brain Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Medulloblastoma", "Refractory Brain Neoplasm", "Refractory Diffuse Intrinsic Pontine Glioma", "Refractory Ependymoma", "Refractory Medulloblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Conventional Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Tensor Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Weighted Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-enhanced MR Perfusion", "type": "PROCEDURE" }, { "name": "Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Spectroscopic Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 71, "start_date": "2015-06-03", "completion_date": "2027-01-16", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-09T04:44:39.607Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02359565" }, { "nct_id": "NCT01992861", "title": "MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Cervical Undifferentiated Carcinoma", "Recurrent Cervical Carcinoma", "Stage IB2 Cervical Cancer", "Stage II Cervical Cancer", "Stage IIA Cervical Cancer", "Stage IIB Cervical Cancer", "Stage III Cervical Cancer", "Stage IIIA Cervical Cancer", "Stage IIIB Cervical Cancer", "Stage IVA Cervical Cancer" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Diffusion Weighted Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "RADIATION" }, { "name": "Magnetic Resonance Spectroscopic Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 51, "start_date": "2014-02-14", "completion_date": "2022-01", "has_results": false, "last_update_posted_date": "2023-06-26", "last_synced_at": "2026-09-09T04:44:39.607Z", "location_count": 4, "location_summary": "Miami, Florida • Maywood, Illinois • Columbus, Ohio + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01992861" }, { "nct_id": "NCT02057874", "title": "3-Tesla MRI Response to TACE in HCC (Liver Cancer)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Primary Hepatocellular Carcinoma", "Advanced Adult Primary Liver Cancer", "Localized Resectable Adult Primary Liver Cancer", "Localized Unresectable Adult Primary Liver Cancer", "Stage A Adult Primary Liver Cancer (BCLC)", "Stage B Adult Primary Liver Cancer (BCLC)" ], "interventions": [ { "name": "3 Tesla Magnetic Resonance Imaging", "type": "DEVICE" }, { "name": "Magnevist® (Intravenous (IV) administration of MRI contrast agent)", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2014-02", "completion_date": "2015-12-04", "has_results": true, "last_update_posted_date": "2018-07-11", "last_synced_at": "2026-09-09T04:44:39.607Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02057874" }, { "nct_id": "NCT01223248", "title": "Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma", "Ovarian Cancer", "Sarcoma", "Bone", "CNS-Spinal CD/MEMBR, NOS", "Lymph Nodes", "Soft Tissue" ], "interventions": [ { "name": "IGIMRT using a single dose of 24 Gy", "type": "RADIATION" }, { "name": "IGIMRT 27 Gy in 3 fractions", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2010-10", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-09-09T04:44:39.607Z", "location_count": 2, "location_summary": "San Francisco, California • New York, New York", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01223248" }, { "nct_id": "NCT02269111", "title": "Quantitative MRI in Assessing Disease in Patients With Brain Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Tumors Metastatic to Brain", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "diffusion-weighted magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "chemical exchange saturation transfer magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "dynamic contrast-enhanced magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "dynamic susceptibility contrast-enhanced magnetic resonance imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2015-04", "completion_date": "2018-05", "has_results": false, "last_update_posted_date": "2018-05-29", "last_synced_at": "2026-09-09T04:44:39.607Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02269111" } ] }